Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
03/09/2026 18:29
BRIEF-Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US Sept 3 (Reuters) - Cipla Ltd CIPL.NS:
CIPLA ANNOUNCES EXCLUSIVE PARTNERSHIP WITH QILU PHARMACEUTICAL FOR THE LICENSING AND SUPPLY OF BIOSIMILAR TO KEYTRUDA® (PEMBROLIZUMAB) IN THE US
CIPLA - QILU TO DEVELOP AND SUPPLY QL2107; CIPLA USA TO COMMERCIALIZE IN US
Source text: ID:nPn4h7SPa
Further company coverage: CIPL.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate